Operational team

Operational team

Team
 » 
Operational team
Read more
Bengt von Mentzer
Portrait photo

Bengt von Mentzer

Founder and Chief scientific advisor
Read more
Read more
Thomas Eskildsen
Portrait photo

Thomas Eskildsen

Senior clinical trial manager
Read more
Read more
Olof Breuer
Portrait photo

Olof Breuer

MD, Clinical pharmacology lead
Read more
Read more
Kerstin Kenne
Portrait photo

Kerstin Kenne

Scientific advisor, Toxicology
Read more
Read more
Christina Balslev Rindshøj
Portrait photo

Christina Balslev Rindshøj

Regulatory affairs advisor
Read more
Read more
Rikke Winther
Portrait photo

Rikke Winther

Scientific advisor, Clinical
Read more
Read more
Per von Mentzer
Portrait photo

Per von Mentzer

Chief executive officer and board member since 2018
Read more
Read more
Bengt von Mentzer
Portrait photo

Bengt von Mentzer

Founder and Chief scientific advisor, board member since 2008.
Read more
Read more
David Kendall
Portrait photo

David Kendall

Chief scientific officer and board member since 2010.
Read more

Latest news

View all
October 3, 2023

Phase I study completed for PN6047

In August 2022, PharmNovo initiated the First-In-Human, (FIH), clinical study for the company’s drug candidate PN6047, aimed at evaluating its safety and tolerability. By August 2023, the study was completed, involving 104 subjects across 13 cohorts, which included both Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) cohorts. Each cohort consisted of 8 subjects, with 6 receiving active treatment and 2 receiving placebo.

Read more
October 3, 2023

PharmNovo presented at the BioStock Investor Meeting

PharmNovo participated at the BioStock Investor Meeting in Stockholm on September 20. Our CEO presented the development and phase I clinical study of our drug candidate PN6047, which is in its final phase.

Read more
September 28, 2023

No abuse potential shown in preclinical studies

We are delighted to share promising preclinical results for our innovative drug candidate PN6047, further confirming its safety profile. PN6047 is designed to provide relief from neuropathic pain, and these findings reinforce our commitment to safe and effective pain management as we prepare for Phase II trials in 2024.

Read more
September 10, 2023

Latest progress from PharmNovo at EFIC

PharmNovo will participate in the 13th Congress of the European Pain Federation, EFIC, in Budapest from 20-22 September. The EFIC Congress is the largest international congress on pain.

Read more